Management of Methylphenidate-Induced Appetite Suppression in Teens

Introduction to Stimulant Alternatives

The American Academy of Pediatrics recommends that patients who fail to respond to or cannot tolerate one stimulant class should be switched to the other stimulant class before considering non-stimulants, as the overall response rate when both psychostimulants are tried approaches 80-90% 1, 2
Both methylphenidate and amphetamine demonstrate equivalent efficacy for ADHD core symptoms with large effect sizes, but individual patients may respond to either amphetamine or methylphenidate with markedly different side effect profiles 1, 2

Give the stimulant with meals and provide a high-calorie drink or snack late in the evening when stimulant effects have worn off 3
Consider long-acting formulations which may produce less pronounced peak effects and potentially milder appetite suppression compared to immediate-release formulations 1, 4
Monitor growth parameters regularly (height and weight), as stimulants cause small but measurable decrements in growth velocity (approximately 1-2 cm reduction in height over 2-3 years), though this effect diminishes by the third year and final adult height appears unaffected 4

Atomoxetine has an effect size of approximately 0.7 (compared to 1.0 for stimulants) and causes initial gastrointestinal symptoms and decreased appetite, though potentially less severe than stimulants 4
Extended-release guanfacine also has an effect size of approximately 0.7 and may cause less appetite suppression, though somnolence and fatigue are common (occurring in 15-20% of patients) 4, 5
Both non-stimulants are considerably less effective than stimulants and should only be used when stimulants have failed or are contraindicated 1, 4

Screen for substance abuse before prescribing any stimulant to adolescents, as diversion and misuse are particular concerns in this age group 1
For adolescents who drive, ensure adequate medication coverage during driving hours, which may require late-afternoon dosing or longer-acting formulations 1

Measure blood pressure and heart rate at baseline and regularly during treatment, as stimulants cause small increases (1-4 mmHg BP, 1-2 bpm HR on average) that may be clinically relevant 4
Track height and weight at each visit, plotting on growth charts to detect growth velocity changes early 4
Assess for psychiatric symptoms including mood changes, irritability, anxiety, or psychotic symptoms, which occur uncommonly but require immediate attention 4